People suffering from severe asthma were offered new hope after a jab was approved for use on the NHS. The National Institute for Health and Clinical Excellence (Nice) gave the go-ahead to omalizumab (Xolair) to treat severe persistent allergic asthma. The jab has been hailed as a breakthrough in stopping the body reacting severely to pollen, skin particles produced by cats and house-dust mite droppings.
Link to Article
Additional Stories
No comments:
Post a Comment